TMF Reference Model. Topline results of 2014 TMF Survey #4. August 2014 Fran Ross TMF Survey Sub-team

Size: px
Start display at page:

Download "TMF Reference Model. Topline results of 2014 TMF Survey #4. August 2014 Fran Ross TMF Survey Sub-team"

Transcription

1 TMF Reference Model Topline results of 2014 TMF Survey #4 August 2014 Fran Ross TMF Survey Sub-team

2 Trial Master File (TMF) Survey Background TMF Survey purpose: industry-wide, gather insight into quality, cost and effectiveness drivers of TMF management, including: Knowledge and use of TMF Reference Model Changes in TMF management and processes Impacts of electronic TMF and e-investigator Site File Insight into health authority inspection trends Data for 2014 Survey #4 was collected in May to July of 2014 Previous surveys were conducted in 2010, 2012, and 2013 A survey team will regroup for work on the fifth TMF Survey in 1Q2015. Your feedback, insight and participation are enthusiastically welcomed. The TMF Survey sub-team and the Trial Master File Reference Model (TMF RM) initiative is a subgroup of the Document and Records Management SIAC of the Drug Information Association 2014 TMF Survey 2

3 Trial Master File (TMF) Survey Background TMF Survey purpose: industry-wide, gather insight into quality, cost and effectiveness drivers of TMF management, including: Knowledge and use of TMF Reference Model TMF management pain points Paper vs electronic TMF Data for the 2014 was collected from May to July 2014 This TMF Survey has been conducted as an initiative of the TMF Reference Model (TMF RM) and is performed annually. The TMF RM committee and leadership operate in coordination with the EDM Reference Model as initiatives of the Document and Records Management (DRM) Community in the DIA 2014 TMF Survey 3

4 Report Sections Respondent Demographics TMF / etmf Insights TMF Metrics TMF Reference Model Use Inspection Trends Electronic Investigator Site File (eisf) 2014 TMF Survey 4

5 RESPONDENT DEMOGRAPHICS 5

6 Respondent Organization Type 231 Evaluable Responses Sponsor organizations majority respondents (57%) Your organization type: 10% 6% 4% Sponsor Site 9% 13% 2% 57% CRO Consultant Vendor 2014 TMF Survey 6

7 Respondent Location Where are you located? 1% 5% 62% 32% Africa Asia Pacific Europe Latin America USA / Canada 0% 2014 TMF Survey 7

8 Trial Outsourcing Profile What percentage of current Phase II/III trials are fully outsourced to CROs? (select closest percentage) 30% 4% 18% 100% fully out sourced 76 99% 51 75% 25% 26 50% 0 25% 9% Not applicable 14% 2014 TMF Survey 8

9 Active Trials Indicate the number of active trials at your organization 3% 23% 13% 9% 10% 13% 29% 1 to 4 5 to to to to to TMF Survey 9

10 TMF / etmf INSIGHTS 10

11 TMF SOP Adherence Does your organization have and follow a TMF SOP? 1% 0% 1% 11% Yes, followed consistently Yes, followed inconsistently Yes, not followed 26% No, in development 61% No, no plans for SOP Not required 2014 TMF Survey 11

12 Paper TMF or Electronic TMF (etmf) What format is your TMF file of record? 1% All Inspectable TMF in paper 33% All Inspectable etmf 58% Combination of inspectable paper and inspectable etmf 8% Other (please comment) 2014 TMF Survey 12

13 etmf Status What is the status of your organization's etmf? 14.5% 3.9% 3.3% We currently use etmf Evaluating 44.1% Actively Planning 15.1% Actively Building/Implementing Not Considering 19.1% Not Applicable / Unknown 2014 TMF Survey 13

14 etmf Duration How long has your etmf been in production? 2% 15% 19% 34% 15% 15% Less than 1 Year 1 Year 2 3 Years 4 5 years 6 or more years Other (please specify) 2014 TMF Survey 14

15 More Than One etmf? Do you use more than one etmf system? 3% No 22% Yes we have multiple etmfs 14% 61% Yes ours and our partner's (e.g. CRO) etmfs Other (please specify) 2014 TMF Survey 15

16 Issues When Using More Than One etmf System Which of the following issues do you encounter using more than one etmf system? (select all that apply) 80.0% 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% None Increased effort for reconcilation Difficulty establishing file of record User Confusion Increased cost burden Increased complication with submission processing 2014 TMF Survey 16

17 etmf Archive Process What is the etmf post trial "archive" process"? 3% 14% 28% No archive process, remains in system Electronic archive, remains in system 7% Electronic archive, moved to another system Stored on external media 17% Printed hard copy 31% Other (please specify) 2014 TMF Survey 17

18 TMF METRICS 18

19 TMF Metrics Program Do you have a TMF metrics program in place? 4% Yes, we have a metrics program. 24% 24% No, but we are evaluating the need for a program. 11% 37% No, but we are implementing a metrics program. No, we are not planning a metrics program Other (please specify) 2014 TMF Survey 19

20 TMF Metrics Program Measurements What do you measure in your TMF Metrics Program? (select all that apply) 80.0% 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% Completeness of TMF Document Classification Quality (filed accurately / assigned to correct document type) Document Metadata Quality (correctness of metadata) Image Quality (e.g. missing/extra pages, skewing, etc.) System usage (etmf) (e.g., daily or weekly logins) Timeliness of processing TMF documents Volume of documents processed Other (please specify) 2014 TMF Survey 20

21 TMF Metrics - Cost Do you measure TMF costs? 8% 5% 36% Yes No N/A Other (please specify) 51% 2014 TMF Survey 21

22 TMF Metrics Cost Efficiency Opinion Do you believe your TMF is cost efficient? 18% 9% 21% 24% Very cost efficient Somewhat Neutral Somewhat inefficient Very inefficient 28% 2014 TMF Survey 22

23 TMF REFERENCE MODEL USE 23

24 TMF Reference Model Awareness Are you aware of the TMF Reference Model? 5% Yes No 95% 2014 TMF Survey 24

25 TMF Reference Model Use Is your organization using the TMF Reference Model? 0% 11% Yes No 25% 64% Don't Know Not Applicable (Vendor, Health Authority, Consultant, Other) 2014 TMF Survey 25

26 TMF Reference Model for paper or etmf? My organization is using the Model for... 1% 6% 11% 43% 39% Paper TMFs only etmfs only Both paper and etmfs Don't know Other (please specify) 2014 TMF Survey 26

27 TMF Reference Model Use in New and Ongoing Trials My organization is using the Model in... (select all that apply) 100.0% 90.0% 80.0% 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% New TMFs Ongoing studies with restructured TMF Ongoing studies with documents added to/removed from TMF Closed TMFs 2014 TMF Survey 27

28 TMF Reference Model Adoption Practices Has your organization adopted the Model as is, without any change? 12% 27% Yes, adopted as is No, adapted with changes Other (please specify) 61% 2014 TMF Survey 28

29 TMF Reference Model Adoption Methods In adopting the Model, my organization is 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% Adding artifacts Condensing artifacts Branching artifacts into sub-artifacts Changing the RM numbering system Restructuring the zones Other changes (please specify) 2014 TMF Survey 29

30 TMF Reference Model Adoption Impacts 80.0% 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% Updating/planning to change SOPs Creating/updating guidance or best practice documents Mapping TMF structure to model Changing active TMFs to reflect model Other (please specify) 2014 TMF Survey 30

31 INSPECTION TRENDS 31

32 Inspector Opinion TMF Modality Do you have a preference for clinical trial documentation / TMF inspection modality? 29% 14% 14% etmf Paper TMF Doesn't matter Depends (comment) 43% 2014 TMF Survey 32

33 Inspector Opinion etmf Inspection Use Are you / would you be comfortable completing an inspection in an etmf? 43% 57% Yes No Depends (comment) 0% 2014 TMF Survey 33

34 Inspector Opinion TMF Reference Model Do you find the TMF Reference Model supports activities in clinical trial inspections 29% Yes 71% 0% No Not aware of the TMF Reference Model 2014 TMF Survey 34

35 Sponsor Inspection History 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% Have you had regulatory agency / health authority inspections of your etmf? (select all that apply) No etmf Inspections US FDA EU EMA UK MHRA Japan PMDA Australia/New Zealand Brazil ANVISA China SFDA Other (please specify) 2014 TMF Survey 35

36 Sponsor Remote Inspection History Have you yet had a remote (off premise) inspection by any regulatory agency / health authority? 21% 24% Yes No Unknown 55% 2014 TMF Survey 36

37 Sponsor Inspection History Paper Requests 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% Has any inspector refused to use etmf and required paper print out of TMF? No refusal US FDA EU EMA UK MHRA Japan PMDA Australia/New Zealand Brazil ANVISA China SFDA Other (please specify) 2014 TMF Survey 37

38 Sponsor Inspection History etmf Resistance 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% Has any inspector refused to use paper and required access to etmf? No refusal US FDA EU EMA UK MHRA Japan PMDA Australia/New Zealand Brazil ANVISA China SFDA Other (please specify) 2014 TMF Survey 38

39 Sponsor Opinion - Inspection Preparation Impact Has the etmf helped ease burdens of audits / inspections? 10% 24% 66% Yes No Unknown 2014 TMF Survey 39

40 Sponsor Opinion - etmf Inspection Impact Have auditors or inspectors found the etmf easier to inspect using your etmf software? 34% 31% Yes No 7% 28% We do not allow inspector direct access to the etmf Unknown 2014 TMF Survey 40

41 Sponsor Opinion etmf Impact Unannounced Inspections Has the etmf proved a benefit in allowing you to support unannounced inspections? 31% 55% Yes No Unknown 14% 2014 TMF Survey 41

42 ELECTRONIC INVESTIGATOR SITE FILE (e-isf) 42

43 etmf Externalization Does your etmf externalize content to clinical trial sites (e.g. Investigator Portal)? 31% 8% 20% We currently externalize content Evaluating Actively Planning 18% 12% 11% Actively Building/Implementing Not Considering Not Applicable / Unknown 2014 TMF Survey 43

44 eisf Usage Are electronic Investigator Site Files (eisf) being used in your trials? 13% Yes No 87% 2014 TMF Survey 44

45 Percentage of Trials with eisf What percent of your trials have an electronic Investigator Site File (eisf)? 21% 10% 37% 0 25% 26 50% 51 75% % 32% 2014 TMF Survey 45

46 eisf Excluded Content 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% Which of the following documents, if any, are NOT stored in the eisf (select all that apply) Subject Signed Informed Consent Signed Financial Disclosures Signed Contracts Unblinded Subject Identification Log Payment/Finance Documents 2014 TMF Survey 46

47 eisf Archive Process What is the eisf post trial "archive" process? 5% 5% 16% 5% 32% No archive process, remains in system Electronic archive, remains in system Electronic archive, moved to another system Stored on external media Printed hard copy 37% Other (please specify) 2014 TMF Survey 47

48 eisf Technology Control Is the eisf the site's technology or sponsor / CRO's technology? 0% 21% Site Sponsor / CRO Other (please specify) 79% 2014 TMF Survey 48

49 Barriers to eisf uptake If no eisf, why not? (choose all that apply) 50.0% 45.0% 40.0% 35.0% 30.0% 25.0% 20.0% 15.0% 10.0% 5.0% 0.0% Technical Constraints Regulatory concerns/barriers Legal concerns/barriers Local country concerns Site refusal Financial barriers Not considered Other (please specify) 2014 TMF Survey 49

50 TMF Reference Model Participate! Contact co-chairs to join TMF Ref Model Team: Karen Roy, Lisa Mulcahy, To stay up to date on TMF Ref Model team progress and active discussions, read the blog: Join Linked In group TMF Reference Model The TMF Ref Model and overview information is free and available here TMF Survey 50

51 TMF 2014 Survey team THANK YOU! Shah Ashraf Kathie Clark Fran Ross Steve Scribner Thanks to Chris McSpiritt for preliminary results deck support! 2014 TMF Survey 51

Chair of the TMF Reference Model Steering Committee Co-founder of the TMF Reference Model with Lisa Mulcahy Chief Strategy Officer, Phlexglobal

Chair of the TMF Reference Model Steering Committee Co-founder of the TMF Reference Model with Lisa Mulcahy Chief Strategy Officer, Phlexglobal Karen Roy Chair of the TMF Reference Model Steering Committee Co-founder of the TMF Reference Model with Lisa Mulcahy Chief Strategy Officer, Phlexglobal Paul Fenton Co-chair of the TMF Reference Model

More information

11 Hidden Features of electronic Trial Master Files (etmfs) to Optimize the Value of Your etmf

11 Hidden Features of electronic Trial Master Files (etmfs) to Optimize the Value of Your etmf 11 Hidden Features of electronic Trial Master Files (etmfs) to Optimize the Value of Your etmf Penelope K. Manasco, M.D. CEO MANA RBM pmanasco@manarbm.com etmfs are rapidly replacing paper trial master

More information

Veeva 2017 Unified Clinical Operations Survey

Veeva 2017 Unified Clinical Operations Survey PRELIMINARY FINDINGS Veeva 2017 Unified Clinical Operations Survey The Veeva 2017 Unified Clinical Operations Survey examines the life sciences industry s progress toward a unified clinical environment

More information

Veeva 2015 Paperless TMF Survey: Annual Report

Veeva 2015 Paperless TMF Survey: Annual Report Veeva 2015 Paperless TMF Survey: Annual Report REMOVING PAPER FROM THE PROCESS The Veeva 2015 Paperless TMF Survey explores the life sciences industry s progress toward paperless clinical trials by gathering

More information

etmf From Libraries of Paper to Electronic Filing Cabinets to Databases

etmf From Libraries of Paper to Electronic Filing Cabinets to Databases ClinTech 2014 etmf From Libraries of Paper to Electronic Filing Cabinets to Databases 12 March 2014 Kelley Robinson TMF Process Analyst Why an etmf Platform? A dynamic solution to enable active contribution,

More information

Veeva 2016 Paperless TMF Survey

Veeva 2016 Paperless TMF Survey Veeva 2016 Paperless TMF Survey The Veeva 2016 Paperless TMF Survey explores the life sciences industry s progress in streamlining clinical trials and unifying clinical operations. It represents the experiences

More information

Intralinks Studyspace : Electronic Investigator-Controlled Site File (eisf)

Intralinks Studyspace : Electronic Investigator-Controlled Site File (eisf) Intralinks Studyspace : Electronic Investigator-Controlled Site File (eisf) Introduction Intralinks Studyspace: Electronic Investigator-Controlled Site File (eisf) Intralinks Studyspace eisf solution is

More information

Constructing an etmf 12/2/2011. consider your current etmf structure!! The do s and don ts of EDM. Disclaimer

Constructing an etmf 12/2/2011. consider your current etmf structure!! The do s and don ts of EDM. Disclaimer Constructing an etmf The do s and don ts of EDM Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug

More information

Points to Consider When Developing a TMF (Trial Master File) Strategy

Points to Consider When Developing a TMF (Trial Master File) Strategy PHLEXGLOBAL WHITE PAPER Points to Consider When Developing a TMF (Trial Master File) Strategy Presented By: Karen Redding Global Business Development Director Phlexglobal Ltd. kredding@phlexglobal.com

More information

Welcome Steering Committee Update Reminder to Vote! TMF RM Community ICH Update Implementation and User guide Change Control Board Exchange mechanism

Welcome Steering Committee Update Reminder to Vote! TMF RM Community ICH Update Implementation and User guide Change Control Board Exchange mechanism 19 March 2018 Welcome Steering Committee Update Reminder to Vote! TMF RM Community ICH Update Implementation and User guide Change Control Board Exchange mechanism Other Subgroup activity update MHRA Data

More information

Veeva 2015 Paperless TMF Survey: Annual CRO Report

Veeva 2015 Paperless TMF Survey: Annual CRO Report Veeva 2015 Paperless TMF Survey: Annual CRO Report The Veeva 2015 Paperless TMF Survey: Annual CRO Report explores the progress made by contract research organizations (CROs) toward paperless clinical

More information

Top Challenges with Late Stage Trial Master Files

Top Challenges with Late Stage Trial Master Files Top Challenges with Late Stage Trial Master Files The transition from a paper to an electronic Trial Master File (TMF) system is a significant task. In many cases, some pharma and biotech firms (sponsors)

More information

Trial Master File Reference Model. Project Charter. Review, Testing, and Ratification of the etmf Exchange Mechanism Standard, Version 1

Trial Master File Reference Model. Project Charter. Review, Testing, and Ratification of the etmf Exchange Mechanism Standard, Version 1 Trial Master File Reference Model Project Charter Review, Testing, and Ratification of the etmf Exchange Mechanism Standard, Version 1 Prepared by The Exchange Mechanism Standard Subgroup of the TMF Reference

More information

2016 Paperless TMF Survey: CRO Report Michael Burton Director, Vault Clinical. Copyright 2017 Veeva Systems Inc., all rights reserved veeva.

2016 Paperless TMF Survey: CRO Report Michael Burton Director, Vault Clinical. Copyright 2017 Veeva Systems Inc., all rights reserved veeva. 2016 Paperless TMF Survey: CRO Report Michael Burton Director, Vault Clinical Third Annual Veeva Paperless TMF Survey: CRO Report Understand the impact of etmf adoption among CROs on TMF processes Examine

More information

GCP Regulatory Inspection Readiness. March 29, 2018

GCP Regulatory Inspection Readiness. March 29, 2018 GCP Regulatory Inspection Readiness March 29, 2018 GCP Regulatory Inspection Readiness Panelists: Kathy Goldstein, PharmD, Sr. Director, R&D Quality and Compliance, Alexion Pharmaceuticals, Inc. David

More information

Phlexglobal Whitepaper

Phlexglobal Whitepaper Phlexglobal Whitepaper Dashboard Metrics: The Solution to Document Risk-Based Monitoring Presented By: Claire Jarmey-Swan Product Development Manager Email: CJarmey-Swan@phlexglobal.com Phlexglobal Inc.

More information

FULL TABLE OF CONTENTS AND CHARTS & GRAPHICS

FULL TABLE OF CONTENTS AND CHARTS & GRAPHICS TRIAL MASTER FILE MANAGEMENT UPHOLD DOCUMENTATION PROCESSES TO SAFEGUARD GOOD CLINICAL PRACTICES FULL TABLE OF CONTENTS AND CHARTS & GRAPHICS 68 T.W. Alexander Dr. P.O. Box 13628 Research Triangle Park,

More information

Building an etmf on Documentum. Sanofi-Pasteur s experience

Building an etmf on Documentum. Sanofi-Pasteur s experience Building an etmf on Documentum Béatrice Neyret Director and Global Head, Clinical Documentation Sanofi-Pasteur Momentum Berlin, November 2, 2011 1 Agenda Introduction What is the TMF? The TMF at Sanofi-Pasteur

More information

Trends in pharmacovigilance inspection deviations. 8th Scandinavian SARQA/DKG Quality Assurance Conference

Trends in pharmacovigilance inspection deviations. 8th Scandinavian SARQA/DKG Quality Assurance Conference Trends in pharmacovigilance inspection deviations 8th Scandinavian SARQA/DKG Quality Assurance Conference Thorsten Jørgensen, PV Auditor, LEO Global Quality 1 Disclaimer This presentation does not represent

More information

What you missed at the 3 rd Trial Master File Summit January 28-29, Alexandria, VA.

What you missed at the 3 rd Trial Master File Summit January 28-29, Alexandria, VA. What you missed at the 3 rd Trial Master File Summit January 28-29, 2014 - Alexandria, VA www.exlevents.com/tmf Why an etmf Platform? A dynamic solution to enable active contribution, organization, maintenance

More information

Regulatory requirements and registration process of Generic Drugs in China

Regulatory requirements and registration process of Generic Drugs in China 13 Regulatory requirements and registration process of Generic Drugs in China Jitendra Kumar Badjatya Deputy Manager-DRA, Montajat Pharmaceutical Company Limited, Dammam, KSA jeetbadjatya@gmail.com ABSTRACT

More information

etmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector

etmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector etmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector Agenda EU Legislation and Guidance News/Updates relating to TMF Structure and Content of e/tmf Inspecting etmfs

More information

Data Integrity in Clinical Trials the Sponsor Perspective

Data Integrity in Clinical Trials the Sponsor Perspective Data Integrity in Clinical Trials the Sponsor Perspective Maximilian Stroebe, GSK Vaccines Three differences to Commercial Manufacturing Long process chains Source Data, Clinical Sites and Outsourcing

More information

Inspections: an academic perspective

Inspections: an academic perspective Inspections: an academic perspective Patricia Henley Quality and Governance Manager Head, Research Governance & Integrity Office London School of Hygiene & Tropical Medicine Email: patricia.henley@lshtm.ac.uk

More information

Please note that these comments and the identity of the sender will be published unless a specific justified objection is received.

Please note that these comments and the identity of the sender will be published unless a specific justified objection is received. 11.07.2017 Submission of comments on 'Guideline on GCP compliance in relation to trial master file (paper and/or electronic) for content, management, archiving, audit and inspection of clinical trials'

More information

Annex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO

Annex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO 23 August 2017 EMA/431267/2016 Annex IV to guidance for the conduct of good clinical practice inspections sponsor Adopted by GCP Inspectors Working Group (GCP IWG) 29 November 2017 Keywords GCP inspection,

More information

Implementation Guide 14-Mar-2018

Implementation Guide 14-Mar-2018 Implementation Guide 14-Mar-2018 This document is freely distributable and is based on the opinions of the TMF Reference Model User Guide and Implementation Subgroup. Identification Authors Name Organization

More information

Agile-ing Your TMF Using Software Development Methodology to Maintain Quality in the TMF

Agile-ing Your TMF Using Software Development Methodology to Maintain Quality in the TMF Agile-ing Your TMF Using Software Development Methodology to Maintain Quality in the TMF Presented January 16, 2018 7 th Trial Master File Summit Orlando, FL Terri Baker Expert Services Wingspan, a QuintilesIMS

More information

PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance

PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance PHLEXGLOBAL WHITE PAPER PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance Presented By: Karen Redding Global Business Development Director Phlexglobal, Ltd. kredding@phlexglobal.com

More information

EXECUTIVE SUMMARY 4TH TRIAL MASTER FILE SUMMIT. Join the Conversation Group: Good Clinical Records Management.

EXECUTIVE SUMMARY 4TH TRIAL MASTER FILE SUMMIT. Join the Conversation Group: Good Clinical Records Management. EXECUTIVE SUMMARY 4TH TRIAL MASTER FILE SUMMIT Join the Conversation Group: Good Clinical Records Management CONTENTS INTRODUCTION 3 PRESENTATIONS 4 RESOURCES FOR INFORMATION AND DISCUSSION 11 INTRODUCTION

More information

Your Complete Quality Solution Provider for the Life Science Industry

Your Complete Quality Solution Provider for the Life Science Industry Your Complete Quality Solution Provider for the Life Science Industry PQE at-a-glance Our broad services portfolio, extensive experience, effective project management, and exceptional cost effectiveness,

More information

Advance Information Management through etmf and CTMS Convergence. Troy Deck Wingspan Technology

Advance Information Management through etmf and CTMS Convergence. Troy Deck Wingspan Technology Advance Information Management through etmf and CTMS Convergence Troy Deck Wingspan Technology Agenda Purpose of and Intersections between etmf and CTMS Benefits of Integration Challenges of Integration

More information

Good Clinical Practice (GCP) & Clinical Trial Registries

Good Clinical Practice (GCP) & Clinical Trial Registries Good Clinical Practice (GCP) & Clinical Trial Registries The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practice Forum November 14-17, 2004 Kate Maloney, RN, MS, CPHQ Manager,

More information

REQUIREMENTS OF PLASMA COLLECTION FOR PDMPs IPFA, YOGYAKARTA. March 3, 2017

REQUIREMENTS OF PLASMA COLLECTION FOR PDMPs IPFA, YOGYAKARTA. March 3, 2017 REQUIREMENTS OF PLASMA COLLECTION FOR PDMPs IPFA, YOGYAKARTA March 3, 2017 OVERVIEW Recovered plasma requirements: EU fractionator point of view Collection of plasma Quality and audit requirements Safety

More information

DATA INTEGRITY IN CLINICAL RESEARCH. Singapore Clinical Research Professional (CRP) Forum 25 August 2017

DATA INTEGRITY IN CLINICAL RESEARCH. Singapore Clinical Research Professional (CRP) Forum 25 August 2017 DATA INTEGRITY IN CLINICAL RESEARCH Singapore Clinical Research Professional (CRP) Forum 25 August 2017 Welcome! David W. Fryrear Senior Director R&D Quality Assurance Joined AbbVie in 2013 Responsibilities

More information

Index of Standard Operating Procedures for all research Sponsored by the UHL

Index of Standard Operating Procedures for all research Sponsored by the UHL University Hospitals of Leicester NHS Trust () Index of Standard Operating Procedures for all research Sponsored by the March Please note that with effect from 2015, all SOPs and Appendices use the same

More information

AMI MQP Market & Regulatory Analysis. Kyle Cayabyab Jameel Galloway Matt Hammond Meagan Ward

AMI MQP Market & Regulatory Analysis. Kyle Cayabyab Jameel Galloway Matt Hammond Meagan Ward AMI MQP Market & Regulatory Analysis Kyle Cayabyab Jameel Galloway Matt Hammond Meagan Ward Overview Percentage PERCENT ARRHYTHMIA CASES THAT ARE AF 70 60 50 40 30 20 10 0 Percent Arrhythmia Cases that

More information

INVESTIGATOR SITE FILES SUMMIT

INVESTIGATOR SITE FILES SUMMIT From the creators of the TMF series INVESTIGATOR SITE FILES SUMMIT Best Practices for Ensuring Compliant, Timely and Quality ISF Management for CROs, Sponsors and Sites SEPTEMBER 19-20, 2016 WYNDHAM BOSTON

More information

Veeva 2018 Unified Clinical Operations Survey

Veeva 2018 Unified Clinical Operations Survey PRELIMINARY FINDINGS Veeva 2018 Unified Clinical Operations Survey The Veeva 2018 Unified Clinical Operations Survey examines the life sciences industry s progress toward a unified clinical environment

More information

2013/2014 Report

2013/2014 Report 2013/2014 Staying@Work Report U.S. Executive Summary Introduction U.S. organizations have long looked to health and productivity programs as one way to keep workers healthier and stem the tide of higher

More information

FDA Perspective on International Clinical Trials

FDA Perspective on International Clinical Trials FDA Perspective on International Clinical Trials Kassa Ayalew, M.D., M.P.H. Division of Clinical Compliance Evaluation (DCCE) Office of Scientific Investigations (OSI) Center for Drug Evaluation and Research

More information

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,

More information

International Supply Chain: How are we handling globalisation? GCP oversight

International Supply Chain: How are we handling globalisation? GCP oversight International Supply Chain: How are we handling globalisation? GCP oversight Susana Almeida, PhD Senior Director, European Operations Inflamax Research (Canada) patients quality value sustainability partnership

More information

3M Pulp and Paper Sourcing Policy Progress Report

3M Pulp and Paper Sourcing Policy Progress Report 3M Pulp and Paper Sourcing Policy Progress Report November 2017 3M Pulp and Paper Sourcing Policy Progress Report November 2017 In March 2015, 3M revised our Pulp and Paper Sourcing Policy, which formalizes

More information

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements

More information

Understanding True etmf Requirements:

Understanding True etmf Requirements: www.arisglobal.com A White Paper Presented By ArisGlobal Understanding True etmf Requirements: Meeting Today s Expectations of Industry and Regulatory Agencies Dr. Mathias Poensgen Product Manager, Clinical

More information

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Trial Master File & Investigator Site File SOP number: TM 001 SOP category: Trial Management Version number: 03 Version

More information

GLOBAL MEDICAL DEVICE INDUSTRY OUTLOOK FOR 2018 Based on a survey of more than 4,200 industry professionals

GLOBAL MEDICAL DEVICE INDUSTRY OUTLOOK FOR 2018 Based on a survey of more than 4,200 industry professionals GLOBAL MEDICAL DEVICE INDUSTRY OUTLOOK FOR 2018 Based on a survey of more than 4,200 industry professionals For more information, contact: Stewart Eisenhart Senior Regulatory Analyst marketing@emergogroup.com

More information

MDSAP Me M dical D e D vice S i S ngle Audit Program

MDSAP Me M dical D e D vice S i S ngle Audit Program MDSAP Medical Device Single Audit Program Gary Minks VP, Quality & Regulatory Affairs TÜV SÜD America Inc. gminks@tuvam.com Revision: 2013(09(29 TÜV SÜD America 13(04(29 Slide 1 IMDRF International Medical

More information

CLINICAL TRIALS INSPECTION READINESS SUMMIT. Trial Master Files. Inspection Trends. Metrics Analysis. Partner Oversight

CLINICAL TRIALS INSPECTION READINESS SUMMIT. Trial Master Files. Inspection Trends. Metrics Analysis. Partner Oversight 5th CLINICAL TRIALS INSPECTION READINESS Ensure Inspection Readiness Through Improved Early Preparation Standards, Organized Documentation and Continuous Vigilance from All Stakeholders August 8-9, 2016

More information

Title: Audit and Inspection of the IEC. SOP Code: SOP/24/V1.0. Effective date: 03/05/2013

Title: Audit and Inspection of the IEC. SOP Code: SOP/24/V1.0. Effective date: 03/05/2013 Page 1 of 6 Title: Effective date: 03/05/2013 1 Page 2 of 6 Table of Contents No. Content Page No. 1 Purpose 3 2 Scope 3 3 Responsibility 3 4 Flow chart 3 5 Detailed instructions 3 5.1 Call for an Audit

More information

Document Title: Handling of drug alerts and recalls of IMPs

Document Title: Handling of drug alerts and recalls of IMPs Document Title: Handling of drug alerts and recalls of IMPs Document Number: SOP074 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager,

More information

Drug Registration in BRICS countries: Opportunities and Challenges. Judith ter Horst 1 November 2018

Drug Registration in BRICS countries: Opportunities and Challenges. Judith ter Horst 1 November 2018 Drug Registration in BRICS countries: Opportunities and Challenges Judith ter Horst 1 November 2018 Once a drug reaches Phase1, it s a good idea to start discussions with global regulatory authorities

More information

GLOBAL TRENDS SURVEY REPORT

GLOBAL TRENDS SURVEY REPORT GLOBAL TRENDS SURVEY REPORT + OVERVIEW Clinical trials have become increasingly global in scope. Some countries require testing of drugs in a country before they can be approved for sale in that country.

More information

Topics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities

Topics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities Topics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities audit, audit report and CAPA 1. QUALITY must be guaranteed,

More information

Data Integrity Why is it important? DADM Conference - 22 August 2017

Data Integrity Why is it important? DADM Conference - 22 August 2017 Data Integrity Why is it important? DADM Conference - 22 August 2017 Maibritt Haugaard Møller, System Validation Expert Mette Ravn, Vice President, Data Management, IT and System Validation Overview of

More information

Lake County School District. Quality Assurance & Improvement Program. Internal Self-Assessment for. The Internal Audit Department

Lake County School District. Quality Assurance & Improvement Program. Internal Self-Assessment for. The Internal Audit Department Lake County School District Quality Assurance & Improvement Program Internal Self-Assessment for The Internal Audit Department Fiscal Year 2017 2018 Completed By: Thomas A. Mock, CIA Date: January 31,

More information

Digital Pathology World Market Report 2017

Digital Pathology World Market Report 2017 Research Proposal Publishing October 2018 Market Reports Digital Pathology World Market Report 2017 2017 Edition This is a research proposal for a new Market Report on Digital Pathology, to be published

More information

WHITE PAPER. establishing a regulatory Drug Development Strategy for Asia Pacific

WHITE PAPER. establishing a regulatory Drug Development Strategy for Asia Pacific WHITE PAPER establishing a regulatory Drug Development Strategy for Asia Pacific ppdi.com July 2012 EXECUTIVE SUMMARY As the economic power of China and other Asian countries grows, many biopharmaceutical

More information

About The CMO Survey. Mission. Survey operation. Sponsoring organizations

About The CMO Survey. Mission. Survey operation. Sponsoring organizations About The CMO Survey Mission - To collect and disseminate the opinions of top marketers in order to predict the future of markets, track marketing excellence, and improve the value of marketing in firms

More information

Reflection paper on GCP compliance in relation to trial master files (paper and/or electronic) for management, audit and inspection of clinical trials

Reflection paper on GCP compliance in relation to trial master files (paper and/or electronic) for management, audit and inspection of clinical trials 1 2 3 4 5 6 7 1 February 2013 EMA/INS/GCP/636736/2012 Good Clinical Practice Inspectors Working Group (GCP IWG) Reflection paper on GCP compliance in relation to trial master files (paper and/or electronic)

More information

List of Figures and Tables

List of Figures and Tables 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 Worldwide Pharmaceutical Market Estimated Size, 2001-2008 Major World Markets Population Size and Sales Growth

More information

What you missed at the: 2 nd Clinical Trials Inspection Readiness Summit August 2013 Philadelphia, PA

What you missed at the: 2 nd Clinical Trials Inspection Readiness Summit August 2013 Philadelphia, PA What you missed at the: 2 nd Clinical Trials Inspection Readiness Summit August 2013 Philadelphia, PA For a complete overview download the 2013 Executive Summary Notice of Inspection US FDA European Regulatory

More information

Medical Device Solution

Medical Device Solution Medical Device Solution How to Achieve FDA 21 Part 820 Compliance With Polarion Europe, Middle-East, Africa: Polarion Software GmbH Lautlinger Weg 3 70567 Stuttgart, GERMANY Tel +49 711 489 9969-0 Fax

More information

The Case for ICH E6(R2) Compliance Assessment

The Case for ICH E6(R2) Compliance Assessment The Case for ICH E6(R2) Compliance Assessment The Clinical landscape has become increasingly challenging due to growing demand from regulators and the public for more and better clinical research results.

More information

Index of Standard Operating Procedures for all research Sponsored by the UHL

Index of Standard Operating Procedures for all research Sponsored by the UHL University Hospitals of Leicester NHS Trust () Index of Standard Operating Procedures for all research Sponsored by the October Please note that with effect from 2015, all SOPs and Appendices use the same

More information

List of Figures and Tables

List of Figures and Tables 1.01 p. 50 1.02 p. 50 1.03 p. 51 1.04 p. 51 1.05 p. 52 1.06 p. 52 1.07 p. 53 1.08 p. 53 1.09 p. 54 1.10 p. 54 1.11 p. 55 1.12 p. 55 1.13 p. 56 1.14 p. 56 1.15 p. 57 1.16 p. 57 1.17 p. 58 1.18 p. 58 1.19

More information

EU Unannounced Audits (UAV) Experience To Date Medical Device Single Audit Program (MDSAP) Copyright 2015 BSI. All rights reserved.

EU Unannounced Audits (UAV) Experience To Date Medical Device Single Audit Program (MDSAP) Copyright 2015 BSI. All rights reserved. EU Unannounced Audits (UAV) Experience To Date Medical Device Single Audit Program (MDSAP) Copyright 2015 BSI. All rights reserved. Background & Requirements - See Webinars BSI Website Copyright 2015 BSI.

More information

Case Study: Implementing an e-validation Solution within a BioPharma Company

Case Study: Implementing an e-validation Solution within a BioPharma Company Case Study: Implementing an e-validation Solution within a BioPharma Company Index Company Background Business Drivers Alternatives Identified Solution Justification Implementation Strategy Solution Implementation

More information

Timeliness of TMF Document Submission: from Finalized to Filed

Timeliness of TMF Document Submission: from Finalized to Filed Timeliness of TMF Document Submission: from Finalized to Filed Vittoria Sparacio, MSc CBI s etmf Forum Hyatt at de Bellevue Philadelphia 18 November 2014 Finally my turn to say... I know I am standing

More information

FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up?

FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up? FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up? The following framework of characteristics focuses on attributes that are within the control of investigators and their

More information

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR

More information

Risk-Based Monitoring Update Volume IV

Risk-Based Monitoring Update Volume IV Risk-Based Monitoring Update Volume IV 1. Introduction TransCelerate s Risk-Based Monitoring (RBM) initiative continues to produce tangible outputs during the first half of 2015. The purpose of RBM Update

More information

OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS IN EMERGING MARKET

OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS IN EMERGING MARKET Badjatya et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), 227-232 227 Available online at http://jddtonline.info REVIEW ARTICLE OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS

More information

KINGSMANN CARE GROUP

KINGSMANN CARE GROUP PHARMA CONSULTANTS KINGSMANN CARE GROUP KINGSMANN CONSULTANCY SERVICES Thank you for taking interest in Kingsmann Consultancy Services. Kingsmann Consultancy (KC) is a leading business development-consulting

More information

Harmonizing Manufacturing across Multiple Sites and Regions

Harmonizing Manufacturing across Multiple Sites and Regions Harmonizing Manufacturing across Multiple Sites and Regions ISCT North America Regional Meeting Philadelphia, Pennsylvania Byron T. McAllister B.T. McALLISTER ASSOCIATES, INC. Tuesday, 10 September 2013

More information

Impact of MRCT after ICH E17 fully implement -Industry perspective-

Impact of MRCT after ICH E17 fully implement -Industry perspective- Impact of MRCT after ICH E17 fully implement -Industry perspective- 5th Joint Conference of Taiwan and Japan on Medical Products Regulation December 1st, 2017 Chikara Kikuchi Vice-Chairperson, Drug Evaluation

More information

TRIAL MASTER FILE TMF EUROPEAN SUMMIT OCTOBER, 2014 HILTON LONDON KENSINGTON

TRIAL MASTER FILE TMF EUROPEAN SUMMIT OCTOBER, 2014 HILTON LONDON KENSINGTON 3RD ANNUAL THE ONLY CONFERENCE IN EUROPE COMPLETELY DEDICATED TO TRIAL MASTER FILES! EUROPEAN TRIAL MASTER FILE SUMMIT Maintaining a Compliant Electronic and Paper TMF for Audits and Inspections 20 21

More information

Clinical Trial Disclosure: Current US Situation

Clinical Trial Disclosure: Current US Situation Clinical Trial Disclosure: Current US Situation 1 Huron Consulting Group Inc. All rights reserved. Huron is a management consulting firm and not a CPA firm, and does not provide attest services, audits,

More information

GCP Basics - refresher

GCP Basics - refresher p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History

More information

LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE. Loughborough University (LU) Research Office

LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE. Loughborough University (LU) Research Office LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE Loughborough University (LU) Research Office SOP 1024 LU Study Closedown and End of Study Reporting for NHS Research Sponsored by Loughborough

More information

Document Title: Annual Progress Reports (APRs) Document Number: 056

Document Title: Annual Progress Reports (APRs) Document Number: 056 Document Title: Annual Progress Reports (APRs) Document Number: 056 Version: 1 Ratified by: Committee Date ratified: 30/11/2017 Name of originator/author: Directorate: Department: Name of responsible individual:

More information

High Quality or Poor Quality DB

High Quality or Poor Quality DB The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers,

More information

Research Study Close-down and Archiving Procedures

Research Study Close-down and Archiving Procedures Title: Research Study Close-down and Archiving Procedures Outcome Statement: To inform researchers of the process for closing down research studies, retaining and storing research materials in the Trust.

More information

1 The Clinical Research Coordinator (CRC)... 1

1 The Clinical Research Coordinator (CRC)... 1 TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...

More information

DIA Document & Records Management SIAC

DIA Document & Records Management SIAC DIA Document & Records Management SIAC EDM Reference Model Clinical Domain John Aitken, PhD Director, Regulatory Operations Gilead Sciences Inc Points to Cover Clinical Domain In scope: CTD clinical documents

More information

Welcome. Thank you for joining us. Irina Moissiu, Director Client Relations Laurie Furiness, EVP Operations & Consulting Services

Welcome. Thank you for joining us. Irina Moissiu, Director Client Relations Laurie Furiness, EVP Operations & Consulting Services Welcome Thank you for joining us Irina Moissiu, Director Client Relations Laurie Furiness, EVP Operations & Consulting Services 360 o SERVICE PERFORMANCE MEASUREMENT Sponsor View TM 5 Assessments Available

More information

CDISC Customer Requirements Analyses

CDISC Customer Requirements Analyses Data Model Customer Requirements Analyses Copyright 2003 About The Clinical Data Interchange Standards Consortium () is an open, multidisciplinary, non-profit organization committed to the development

More information

Revision of Chapter 7 Contract Manufacture and Analysis

Revision of Chapter 7 Contract Manufacture and Analysis Revision of Chapter 7 Contract Manufacture and Analysis GMP & Market Compliance Information Day, 14-10-2010 Catherine Neary Inspector Date Insert on Master Slide Slide 1 Overview Purpose of revision to

More information

RESEARCH AUDIT Standard Operating Procedure

RESEARCH AUDIT Standard Operating Procedure Reference Number: UHB 236 Version Number: 2 Date of Next Review: 17 th Oct 2020 Previous Trust/LHB Reference Number: N/A RESEARCH AUDIT Standard Operating Procedure Introduction and Aim As a legal Sponsor

More information

Considerations for Global Development of Orphan Drugs. Ginny Beakes-Read Executive Director Global Regulatory Policy and Intelligence Eisai, Inc.

Considerations for Global Development of Orphan Drugs. Ginny Beakes-Read Executive Director Global Regulatory Policy and Intelligence Eisai, Inc. Considerations for Global Development of Orphan Drugs Ginny Beakes-Read Executive Director Global Regulatory Policy and Intelligence Eisai, Inc. 1 Disclosures Shareholder No Grant/research support No Consultant

More information

Quality and GMP Compliance for Virtual Companies (Pharmaceutical, Medical Device & Biologics Industries)

Quality and GMP Compliance for Virtual Companies (Pharmaceutical, Medical Device & Biologics Industries) Quality and GMP Compliance for Virtual Companies (Pharmaceutical, Medical Device & Biologics Industries) *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY! Today, many companies operate

More information

Section. Clinical CRO Future Industry Leadership & Performance Benchmarking. October, Syndicated Report

Section. Clinical CRO Future Industry Leadership & Performance Benchmarking. October, Syndicated Report Section Clinical CRO Future Industry Leadership & Performance Benchmarking Syndicated Report October, 2015 1 Table of Contents I. Study Background and Methodology 3 II. Study Respondent Demographics 6

More information

Hands-on in Latin America Regulations for Clinical Trials

Hands-on in Latin America Regulations for Clinical Trials Hands-on in Latin America Regulations for Clinical Trials Director: Silvia Zieher VP Clinical Development, Latin America Operations INC Research Disclaimer The views and opinions expressed in the following

More information

Medical Device Single Audit Program (MDSAP) Copyright 2014 BSI. All rights reserved.

Medical Device Single Audit Program (MDSAP) Copyright 2014 BSI. All rights reserved. Medical Device Single Audit Program (MDSAP) International Medical Device Regulatory Forum (IMDRF) IMDRF Management Committee (MC) regulators: Australia, Brazil, Canada, China, the European Union, Japan

More information

How To Be a Global Player in Early Clinical Development? Dr CHONG Chew Lan Executive Director, Medical Research 07-Nov-2014

How To Be a Global Player in Early Clinical Development? Dr CHONG Chew Lan Executive Director, Medical Research 07-Nov-2014 How To Be a Global Player in Early Clinical Development? Dr CHONG Chew Lan Executive Director, Medical Research 07-Nov-2014 Topics Why early clinical development in Asia-Pacific? Access to patient populations

More information

Why Industry Collaborations Matter TransCelerate BioPharma, Inc.

Why Industry Collaborations Matter TransCelerate BioPharma, Inc. Why Industry Collaborations Matter TransCelerate BioPharma, Inc. Jackie Kent Eli Lilly & Co. Shared Investigator Platform Initiative Leader, TransCelerate BioPharma Inc. Introduced by: Carlo Maccarrone

More information

The Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports

The Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports The Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports Dr Brian Edwards Scientific Adviser, Pharmacovigilance & Drug Safety, NDA Regulatory Science Ltd DIA 3rd

More information

GMP Compliance. George Acevedo, CQV Senior Engineer M+W Singapore Pte. Ltd

GMP Compliance. George Acevedo, CQV Senior Engineer M+W Singapore Pte. Ltd GMP Compliance George Acevedo, CQV Senior Engineer M+W Singapore Pte. Ltd June 2017 Overview GMP Definition and Regulation Our Philosophy and Strategy for Compliance Project Lifecycle Deliverables Master

More information

State of the Clinical Trials Industry

State of the Clinical Trials Industry State of the Clinical Trials Industry A Sourcebook of Charts and Statistics 2009 SM 100 N. Washington St., Ste. 301 Boston, MA 02114 www.centerwatch.com ix xxxv 1 41 L I S T O F F I G U R E S A N D T A

More information